Global's Undervalued Small Caps With Insider Activity In March 2025

In This Article:

In March 2025, global markets are grappling with recession concerns and trade policy uncertainties, leading to a period of negative returns across major indices like the S&P 500 and Russell 2000. Despite these challenges, easing inflation in the U.S. offers a glimmer of hope for investors seeking opportunities in small-cap stocks that may be undervalued due to broader market sentiment. In such an environment, stocks with strong fundamentals and insider activity can present intriguing possibilities for those looking at small-cap investments.

Top 10 Undervalued Small Caps With Insider Buying Globally

Name

PE

PS

Discount to Fair Value

Value Rating

Bytes Technology Group

19.2x

4.9x

24.36%

★★★★★★

Nexus Industrial REIT

5.5x

2.8x

25.16%

★★★★★★

Macfarlane Group

10.6x

0.6x

40.01%

★★★★★☆

Robert Walters

NA

0.2x

45.61%

★★★★★☆

Speedy Hire

NA

0.2x

23.36%

★★★★★☆

Minto Apartment Real Estate Investment Trust

8.3x

3.4x

22.13%

★★★★★☆

Hong Leong Asia

8.8x

0.2x

46.66%

★★★★☆☆

Franchise Brands

38.8x

2.0x

26.12%

★★★★☆☆

Sing Investments & Finance

7.3x

3.7x

36.12%

★★★★☆☆

Optima Health

NA

1.6x

42.66%

★★★★☆☆

Click here to see the full list of 145 stocks from our Undervalued Global Small Caps With Insider Buying screener.

Here's a peek at a few of the choices from the screener.

Lycopodium

Simply Wall St Value Rating: ★★★★☆☆

Overview: Lycopodium is an engineering and project management consultancy specializing in resources, process industries, and rail infrastructure, with a market cap of A$0.52 billion.

Operations: Lycopodium generates its revenue primarily from the Resources segment, contributing A$347.83 million, with additional income from Process Industries and Rail Infrastructure. The company experienced fluctuations in its gross profit margin, peaking at 33.28% and most recently recorded at 26.38%. Operating expenses have shown a gradual increase over time, impacting overall profitability despite rising revenues.

PE: 8.8x

Lycopodium, a smaller player in the market, recently updated its fiscal 2025 guidance with expected revenue between A$320 million and A$340 million and net profit after tax ranging from A$37 million to A$43 million. Despite a dip in half-year earnings compared to last year, insider confidence is evident as Steven Chadwick increased their holdings by 8,000 shares worth approximately A$97,572. The company faces higher risk due to reliance on external borrowing but continues to offer dividends with an upcoming fully franked payout of 10 cents per share.